These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29143140)

  • 1. Impact of Conventional Medical Therapy on Bone Mineral Density and Bone Turnover in Adult Patients with X-Linked Hypophosphatemia: A 6-Year Prospective Cohort Study.
    Shanbhogue VV; Hansen S; Jørgensen NR; Beck-Nielsen SS
    Calcif Tissue Int; 2018 Mar; 102(3):321-328. PubMed ID: 29143140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of burosumab in improving phosphate metabolism, bone health, and quality of life in adolescents with X-linked hypophosphatemic rickets.
    Baroncelli GI; Grandone A; Aversa A; Sessa MR; Pelosini C; Michelucci A; Toschi B; Manca M; Isola A; Comberiati P
    Eur J Med Genet; 2024 Aug; 70():104958. PubMed ID: 38950880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression.
    Liu ES; Martins JS; Raimann A; Chae BT; Brooks DJ; Jorgetti V; Bouxsein ML; Demay MB
    J Bone Miner Res; 2016 May; 31(5):929-39. PubMed ID: 26751835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Congenital hypophosphataemia in adults: determinants of bone turnover markers and amelioration of renal phosphate wasting following total parathyroidectomy.
    McKenna MJ; Martin-Grace J; Crowley R; Twomey PJ; Kilbane MT
    J Bone Miner Metab; 2019 Jul; 37(4):685-693. PubMed ID: 30238432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
    Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
    J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status.
    Carpenter TO; Insogna KL; Zhang JH; Ellis B; Nieman S; Simpson C; Olear E; Gundberg CM
    J Clin Endocrinol Metab; 2010 Nov; 95(11):E352-7. PubMed ID: 20685863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of bone mineral density and microarchitectural parameters by DXA and HR-pQCT in 37 children and adults with X-linked hypophosphatemic rickets.
    Colares Neto GP; Pereira RM; Alvarenga JC; Takayama L; Funari MF; Martin RM
    Osteoporos Int; 2017 May; 28(5):1685-1692. PubMed ID: 28194480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eldecalcitol Causes FGF23 Resistance for Pi Reabsorption and Improves Rachitic Bone Phenotypes in the Male Hyp Mouse.
    Kaneko I; Segawa H; Ikuta K; Hanazaki A; Fujii T; Tatsumi S; Kido S; Hasegawa T; Amizuka N; Saito H; Miyamoto KI
    Endocrinology; 2018 Jul; 159(7):2741-2758. PubMed ID: 29878089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Effects of FGF23 c-tail Fc in a Murine Preclinical Model of X-Linked Hypophosphatemia Via the Selective Modulation of Phosphate Reabsorption.
    Johnson K; Levine K; Sergi J; Chamoun J; Roach R; Vekich J; Favis M; Horn M; Cao X; Miller B; Snyder W; Aivazian D; Reagan W; Berryman E; Colangelo J; Markiewicz V; Bagi CM; Brown TP; Coyle A; Mohammadi M; Magram J
    J Bone Miner Res; 2017 Oct; 32(10):2062-2073. PubMed ID: 28600887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations.
    Imel EA; DiMeglio LA; Hui SL; Carpenter TO; Econs MJ
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1846-50. PubMed ID: 20157195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets.
    Harada D; Ueyama K; Oriyama K; Ishiura Y; Kashiwagi H; Yamada H; Seino Y
    J Pediatr Endocrinol Metab; 2021 Jun; 34(6):791-798. PubMed ID: 33837680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23.
    Imel EA; Zhang X; Ruppe MD; Weber TJ; Klausner MA; Ito T; Vergeire M; Humphrey JS; Glorieux FH; Portale AA; Insogna K; Peacock M; Carpenter TO
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2565-73. PubMed ID: 25919461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial.
    Insogna KL; Rauch F; Kamenický P; Ito N; Kubota T; Nakamura A; Zhang L; Mealiffe M; San Martin J; Portale AA
    J Bone Miner Res; 2019 Dec; 34(12):2183-2191. PubMed ID: 31369697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
    Kinoshita Y; Fukumoto S
    Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the trabecular bone score in 35 children and adults with X-linked hypophosphatemic rickets.
    de Paula Colares Neto G; Pereira RMR; Alvarenga JC; Takayama L; de Assis Funari MF; Martin RM
    J Bone Miner Metab; 2023 Sep; 41(5):666-672. PubMed ID: 37418074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China.
    Gao C; Qiao J; Li SS; Yu WJ; He JW; Fu WZ; Zhang ZL
    Osteoporos Int; 2017 Jan; 28(1):211-218. PubMed ID: 27468899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Discrimination Between Tumor-Induced Rickets/Osteomalacia and X-Linked Hypophosphatemia in Chinese Children and Adolescents: A Retrospective Case-Control Study.
    Jiajue R; Ni X; Jin C; Huo L; Wu H; Liu Y; Jin J; Yu W; Lv W; Zhou L; Xia Y; Chi Y; Cui L; Pang Q; Li X; Jiang Y; Wang O; Li M; Xing X; Meng X; Xia W
    J Bone Miner Res; 2021 Sep; 36(9):1739-1748. PubMed ID: 33971042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
    Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W; Sun J; Zhou L; Li Y; Wu X
    J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
    Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
    J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.